key: cord-0745250-guscnrvg
authors: Subbarao, Sathyavani; Campbell, Helen; Ribeiro, Sonia; Clark, Stephen A.; Lucidarme, Jay; Ramsay, Mary; Borrow, Ray; Ladhani, Shamez
title: Invasive Meningococcal Disease, 2011–2020, and Impact of the COVID-19 Pandemic, England
date: 2021-09-03
journal: Emerg Infect Dis
DOI: 10.3201/eid2709.204866
sha: 91d763f6c3a3385828f7c8c39f96d2d4cdbf0623
doc_id: 745250
cord_uid: guscnrvg

Invasive meningococcal disease incidence in England declined from 1.93/100,000 persons (1,016 cases) in 2010–11 to 0.95/100,000 (530 cases) in 2018–19 and 0.74/100,000 in 2019–20 (419 cases). During national lockdown for the coronavirus disease pandemic (April–August 2020), incidence was 75% lower than during April–August 2019.

England. IMD incidence was highest, 1.93 cases/100,000 population (1,016 total cases), during the 2010-11 academic year (September-August) and declined to 1.15 cases /100,000 population for 2013-14 (617 cases) before increasing to 1.51 cases /100,000 population (825 cases) in 2015-16 (Figure) . Adolescent MenACWY and infant 4CMenB immunization programs in 2015 led to additional annual declines in IMD incidence, to 0.95 cases /100,000 population (530 cases) in 2018-19 (incidence rate ratio [IRR] Figure 1 , https://wwwnc.cdc.gov/EID/article/27/9/20-4866-App1.pdf).

IMD cases declined after the national COVID-19 lockdown on March 23, 2020, and remained low during April-August 2020 (Appendix Figure 2 ). During 2018-19, PHE received 12,628 clinical samples from patients with suspected IMD; of these, 462 (4%) tested positive for N. meningitidis. These totals were 9,968 specimens, 401 (4%) positive, during 2019-20 (21% fewer cases). During April-August 2020, a total of 50 (1.8%) of 2,808 samples tested positive for N. meningitidis, compared with 134 (2.7%) of 5,025 samples during the same period in 2019 (p = 0.016). Combining culture-confirmed and PCR-confirmed cases, IMD incidence was 75% lower (IRR 0.25, 95% CI 0.18-0.35) during April-August 2020 than during April-August 2019 (Table) . In contrast, IMD incidence during September 2019-March 2020 (the 7 months before national lockdown) was similar to that for September 2018-March 2019 (IRR 1.06, 95% CI 0.91-1.23). Declines were observed for all age groups and serogroups (Appendix Table) . Table, Figure 1 ).

A total of 45 IMD cases were diagnosed during April-August 2020. The median age of patients was 67 (interquartile range 20-85) years. Linkage with national SARS-CoV-2 data identified 2 patients with IMD who were also positive for SARS-CoV-2 by reverse transcription PCR; both were <90 days of age with late-onset MenB meningitis, and 1 died. Meningitis (with or without septicemia) was proportionally more frequent during the lockdown months compared with the same period in 2019 (27/ Limitations of our study include limited clinical data collected for undiagnosed IMD cases. Cases and case-fatality rates during the lockdown period might also be underestimated if some patients died of IMD at home because they did not seek medical help earlier as a result of the stay at home messaging during lockdown.

In summary, IMD incidence in England has been declining since the early 2000s (8) because of the MenC immunization program and natural trends in MenB disease and further declined because of 2 new meningococcal immunization programs. National lockdown in March 2020 led to a 75% reduction in cases compared with the same period in the previous year, with MenB cases overrepresented. Declines in IMD cases after national lockdown were also reported in France (9) , which is reassuring because viral infections are known to precede IMD; therefore, SARS-CoV-2 could potentially have increased the risk of secondary bacterial infections. Our findings do not support wider vaccination against IMD during the COVID-19 pandemic.

Dr. Subbarao is a microbiology and infectious diseases registrar for Public Health England in London. Her main interests are vaccine-preventable diseases, antimicrobial stewardship, and M. tuberculosis. I nformation about the incidence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among hospitalized pregnant women is available (1) , but information about incidence among pregnant women in the community is not. We therefore quantified the incidence of symptomatic laboratory-confirmed SARS-CoV-2 and influenza infections among pregnant and postpartum women and their infants in Kenya during 2020-2021. The study was reviewed and approved by the Kenya Medical Research Institute Scientific and Ethics Review Unit (KEMRI SSC. 2880) and the Centers for Disease Control and Prevention (CDC) Institutional Review Board (CDC protocol 6709; 45 C.F.R. part 46; 21 C.F.R. part 56). All participants provided written consent.

We adapted an ongoing prospective multiyear influenza mother/baby cohort to include SARS-CoV-2 testing (2) . Pregnant women at <31 weeks of gestation who were seeking prenatal care in Siaya County, Kenya, were approached for enrollment. Those who provided informed consent completed a survey about their demographics and antenatal history and were tested for HIV infection. Women were then phoned or visited at home once weekly until delivery and through their postpartum period, together with their infants, for 6 months to 

Global epidemiology of meningococcal disease

Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis

Emergency meningococcal ACWY vaccination program for teenagers to control group W meningococcal eisease

Vaccination of infants with meningococcal group B vaccine (4CMenB) in England

Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study

Invasive meningococcal disease in England: assessing disease burden through linkage of multiple national data sources

Research and analysis: national COVID-19 surveillance reports: GOV.UK

Invasive meningococcal disease in England and Wales: implications for the introduction of new vaccines

Impact of COVID-19 pandemic and the lockdown on invasive meningococcal disease